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Abstract – High-dose propofol is being investigated for 
its potential antidepressant effect. Propofol is titrated 
to induce burst suppression, a specific EEG pattern. 
However, propofol is difficult to dose due to 
uncertainty in each patient’s pharmacokinetics (PK) 
and pharmacodynamics (PD), and the lack of a 
commercially available monitor of propofol 
concentration. Clinicians currently infer the proper 
drug dose after observing the EEG response to the 
given dose. In this report we share our development of 
an automated controller to optimally administer 
propofol-induced burst suppression. We designed a 
deep deterministic policy gradient (DDPG) algorithm, 
which includes two deep neural networks and relates 
a 2-dimensional action space with a 3-dimensional 
state space. Our DDPG prototype did not satisfy our 
minimum training criteria. However, we share our 
diagnosis of current limitations in training a DDPG-
based RL agent to administer propofol to PK-PD-
simulated in silico patients. We also discuss potential 
solutions to improve RL agent training and 
performance.  
 
I. CLINICAL BACKGROUND 
 
A recent open-label clinical trial at the University 
of Utah demonstrated potential efficacy in propofol’s 
antidepressant effects [1], which are being further studied 
in a randomized controlled trial [2], along with revised 
dosing strategies for propofol.  In the interventional 
group, high-dose propofol is administered to induce a 
specific burst suppression ratio (BSR), which is 
monitored and measured by the BIS™ Monitor 
(Medtronic, Dublin, Ireland), for a specific duration of 
time. Burst suppression is an EEG pattern with alternating 
periods of bursts and quiescence [3], which is similar to 
the EEG patterns observed in electroconvulsive therapy, 
and can alternatively be induced by anesthetics like 
propofol [4] or isoflurane [5] at higher doses.   
 
Figure 1. EEG recording of propofol-induced burst suppression during a high-
dose treatment. The alternating periods of bursts and quiescence are segmented, 
then the ratio is determined by dividing the duration of suppressed EEG activity 
by the duration of the entire epoch of 60 seconds. 
 
Titrating propofol to execute the treatment 
protocol is challenging, because patients' 
pharmacokinetics (PK) and pharmacodynamics (PD) vary 
[6, 7], and cannot be determined easily. Without 
technological assistance to administer propofol, clinicians 
are limited to their intuition and experience. There is 
neither a patient-specific nor standardized process to 
accurately and reliably control propofol-induced burst 
suppression (PIBS). This challenge impacts our clinical 
investigation of propofol’s antidepressant effects.  
 
II. TECHNICAL BACKGROUND 
 
Dosing Based on PK-PD Modeling  
 
PK-PD models can offer a way to conceptualize 
and estimate a patient’s BSR response to administered 
propofol. Parameters from published PK models can be 
individualized to a specific patient by relating the 
propofol administered to the BSR observed in the patient's 
EEG. Effect site concentrations estimated based on the 
individualized PK model can then be used to estimate the 
patient’s pharmacodynamics. Based on individualized 
PK-PD models, the propofol administration can be 
adjusted to achieve the desired levels and durations of 
burst suppression. 
 
The main limitation of this approach is that 
individualizing model parameters would require a careful 
experimental design, which is not practical in the clinical 
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Figure 2. PK simulation of an administered propofol bolus, illustrating the 
accumulation of propofol in the central compartment (red) and in the effect-site 
compartment (blue). Drug accumulation in the effect-site lags behind the 




Figure 3. An example of a sigmoidal PD Hill Curve, relating effect-site 
concentrations to BSR. The concentration-response relationship is nonlinear 
and less sensitive to effect-site concentration changes at the BSR extremes. PD 
model parameters vary between and within patients.  
 
setting. Neither plasma nor effect-site concentrations can 
be verified, because monitors for real-time propofol 
concentration monitoring are not available. Without any 
previous knowledge of how a particular patient responds 
to a drug, clinicians have to rely on population-based 
assumptions.  
 
Without prior individualized estimations of a 
patient’s PK-PD parameters, we can still apply PK-PD 
principles to guide decision making. We can also apply 
known, population-based distributions of PK-PD 
parameters and use machine learning to develop a 
controller that is robust enough to overcome the 
challenges of variability, uncertainty, and nonlinearity in 
PIBS. 
 
Reinforcement Learning  
 
Reinforcement learning (RL) is an intuitive goal-
oriented control technique, which has demonstrated 
proficiency in solving challenging robotic tasks [8] and 
recently in controlling propofol anesthesia [9]. Without an 
explicit control algorithm or an individualized model of 
the patient, an RL “agent” may be able to learn optimal 
behavior on how to dose propofol and control BSR. The 
RL agent learns through experience from a reward 
function and observations from the environment.   
 
 
Figure 4. Block diagram illustrating the general structure of an RL agent’s 
interaction with the environment. The Reward is the feedback that enables 
training and adjusts the determination of future actions.  
 
Though the general structure of reinforcement 
learning is relatively simple, we must integrate the 
method with a simulated patient-environment; and 
properly structure the state space, action space, and 
reward function to effectively train the RL agent. We 
must also consider human factors, when deploying a RL 
agent in the real world.  
 
For example, for commercializing an automated 
dosing system, it may be more practical if the clinician is 
kept in the control loop, due to regulatory concerns. In this 
case, clinicians would manually administer propofol, 
while the RL agent provides guidance to their decision 
making. The number of recommended dosing 
adjustments should be minimized and should not 




In this report, our objective is to develop and 
successfully train a RL agent on simulated patients of the 
same age, weight, and sex. Specifically, we seek to train 
the RL agent to optimally administer propofol and target 
a desired BSR. We hypothesize that our algorithm can 
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Create Simulated Patient   
 
 Published PK-model parameter distributions [7] 
and our group’s own estimations of ke0 (mean ± SD of 
0.136 ± 0.027 1/min), Hill coefficient (6.57 ± 1.70), and 
EC50 (7.40 ± 1.61 mcg/mL) were used to simulate the 
pharmacokinetics and -dynamics of 250 female patients 
with a height of 187 cm, age of 42 years, and weight of 
96 kg. 
 Prior to any agent action, each simulated patient 
received a standard induction: bolus of 3 mg/kg and 
infusion of 300 mcg/kg/min. 
 
 
Define RL State and Action Spaces 
 
The RL state space is defined as: 
1) BSR(t) – Target  
2) |BSR(t) – Target| – |BSR(t-5 seconds) – Target| 
3) Infusion(t) 
The BSR Target was defined as 80% BSR. 
 
The first state-variable tracks the proportional 
BSR error over each time step. The second state-variable 
tracks the change of the absolute BSR error over the last 
5 seconds. The third state-variable tracks the represents 
infusion rate at time t. Though the infusion rate is not 
directly changed by the patient-environment, we believe 
that knowledge of the infusion rate can contribute to the 
RL agent’s learning.  
 
The RL action space is defined as: 
1) Bolus, 0-100 mg 
2) Infusion Rate, 0-400 mcg/kg/min 
 
The time step was defined as 60 seconds.  
 
We determined our action space to reflect the 
real-world decision making in our clinical investigation: 
In order to control BSR, clinicians either delivered a bolus 
dose of propofol or they adjusted the infusion rate. In our 
simulation, the RL agent applies both a bolus and infusion 
rate at each time step, within the ranges specified above. 
 
Create a RL Agent 
 
We applied a deep deterministic policy gradient 
(DDPG) algorithm [10] to create a reinforcement learning 
agent, which can handle continuous-multidimensional 
state and action spaces to solve complex problems 
 
The DDPG-based RL agent is made up of two 
deep neural networks: the actor and the critic. When a 
DDPG-based RL agent processes its observations (states) 
from the environment (patient), the actor network 
determines a set of actions to apply to the environment 
(patient), while the critic network estimates the Q-value 
from the state-action combination. The Q-value is directly 
determined by the reward function and the discounted 
future rewards, according to the Bellman equation [11]. 
The actor is trained to maximize the long-term “reward,” 
while the critic is trained to accurately estimate the Q-
values from the combined state-action space. 
 
The reward function is designed to steer the RL 
agent towards choosing actions based on specific states 
such that its propofol administration choices would 
achieve reaching the desired BSR target:  
 





This reward function is suitable in targeting a 
user-specified BSR during the induction and emergence 
phases of PIBS. Over the course of training, the function 
is designed to reduce the cumulative absolute BSR error. 
 
Training the DDPG Agent 
 
 We followed the DDPG training algorithm 
described by Lillicrap et al. presented at ICLR 2016 [10], 
which specifies how the RL agent is trained, and how the 
actor and critic network weights are adjusted. The training 
was implemented in MATLAB (MathWorks, Natick, 
Massachusetts), using its Reinforcement Learning 
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Figure 5. Block diagram illustrating the general structure of the DDPG 
algorithm, with the actor and critic networks interacting with the patient model. 
The critic network estimates the patient model's Q-value from the state-action 
combination. The Loss guides how the critic network adjusts its weights to 
optimize the critic's estimation. The actor network adjusts its weights according 
to 1) the gradient of critic output with respect to the applied action, and 2) the 
gradient of the actor output with respect to the actor weights, which together 
make up the overall gradient of the actor’s performance based on Estimated 
Q(s,a) [11]. 
 
The RL agent was trained on each of the 250 
simulated patients consecutively and for 120-steps per 
patient, where each step had a duration of 60-seconds. 
Ninety seconds after administering the standard induction 
dose, the RL agent began administering propofol and 
training its deep neural networks.   
 
The Ornstein-Uhlenbeck noise process [12] was 
applied to the actor’s action output before being applied 
to the patient and the critic network. Noise was used to 
promote exploration and avoid convergence toward local 
maxima. We selected a noise variance of 0.500 and 
variance decay rate of 10-5, which reduces the noise 
variance after each time step throughout the entire 
training process. 
 
After completing the training for each patient, we 
recorded the total reward over the 120-step training 
period. We also recorded a 5-patient moving reward 
average, which is based on the average of the total 
rewards of training five consecutive patients. Based on 
the hypothesis, the goal was for the average-absolute BSR 
error to be below 5% (criterion). 
 
Because the reward function is a sum of absolute 
BSR error, we can calculate this average-absolute BSR 
error for each patient by dividing the total reward 
accumulated while training the system with that patient 
by the total time (120 time steps x 60 seconds per time 
step = 7200 seconds).  
 
Our goal is to observe either a patient with an 
average-absolute BSR or an average from treating five 
consecutive patients (throughout any of the 250 patients 
in training) that satisfies the criterion of average-absolute 
BSR error below 5%  
 
V. INITIAL RESULTS  
 
After training on 250 patients, our DDPG agent 
did not meet the training criterion, nor demonstrate 
convergence toward the Critic’s estimated discounted 
long-term reward. The best absolute-average BSR error 
was 7.65% BSR for a single patient, and 14.5% BSR for 
a 5-patient average. The DDPG agent also reported an 
average-absolute BSR error of over 20% BSR in 103 of 
the 250 patients (58.8%). 
 
 
Figure 6 The 5-patient moving reward average (blue) illustrates the DDPG 
agent’s performance as training progresses across patients. The agent’s goal is 
to maximize the Q-value (calculated as the negative absolute BSR error and 
discounted future negative BSR errors) through each time-step and training for 
each patient rewards. Though noise and exploration in the action space can 
explain some fluctuations in performance, the DDPG does not demonstrate 
long-term improvement. An average-absolute BSR error of 20% is illustrated 
(red) to represent the possibility of the DDPG agent becoming “stuck” at the 
upper BSR extremes (~100% BSR) throughout the entire training for one 
patient. A successfully trained DDPG agent would achieve an average-absolute 
BSR error that decreases below the training criterion (yellow) and further 
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Figure 7 Example of training with patient #121, showing BSR, reward, and 
drug administration over time. The drug administration (green) includes a 
combination of a bolus and infusion, which affects the BSR (blue) and its 
corresponding reward (magenta). Even within a patient, we do not observe a 
consistent trend in improving the reward across time steps. The red vertical line 




For this initial design of DDPG agent, its patient-
environment, and training structure, we reject our 
hypothesis, because the DDPG agent did not achieve a 
reward that surpasses the minimum training criteria, 
across the 250 patients it was trained on.  
 
After observing the BSR signals and the rewards 
accumulated for each patient, we suspect that DDPG 
agent may be challenged in reducing BSR at the higher 
BSR extremes. Figure 7 blue reflects the inability to 
moderately decrease BSR (undershoot), while Figure 8 
reflects the continual inability to significantly decrease 
BSR toward the target BSR of 80%. This can potentially 
be attributed to: 1) we cannot apply actions to directly and 
rapidly remove propofol from the patient-environment, 
and 2) the pharmacodynamic relationship between 
propofol concentration and BSR is nonlinear, while our 
reward function is linear.  
 
In order to reduce BSR, we must reduce propofol 
delivery and rely on the patient to clear propofol through 
pharmacokinetics. This clearance is not as rapid as that of 
an administered bolus. In order to reinforce reductions in 
propofol delivery, longer time steps may be required to 
realize more significant changes in BSR and in the 
reward. The agent could benefit from the addition of 
memory and recurrent neural networks, as consecutive 
time steps of reduced propofol input may be required to 
effectively reduce BSR, as well as moderate the decrease 
in BSR over time.   
 
 
Figure 8. Example of a 120-step training with one patient, in which the RL 
agent is unable to decrease drug delivery, drug concentration, and BSR in the 
simulated training subject. The proposed reward function does not provide 
sufficient negative reinforcement to properly adjust the actor.  
 
The reward function, as it was defined, might not 
have been properly “shaped” and can lead to a “vanishing 
gradient” problem in machine learning, in which the actor 
network is unable to adjust its weight, based on the 
feedback provided by the reward function. At the higher 
concentration and BSR extremes, the slope of the 
pharmacodynamic curve diminishes. Given that it is 
already difficult to reduce concentration, reducing BSR 
also becomes more difficult, while the current rewards 
function relies on changes in BSR magnitude. Thus, the 
changes in rewards across the action space would also 
diminish at the upper BSR extremes. This directly 
impacts the gradient of the policy’s performance, which 





We created a PK-PD patient-model and 
integrated it into a reinforcement learning algorithm. Our 
current RL agent did not satisfy our minimum criterion 
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and was unable to converge toward higher rewards and a 
lower average-absolute BSR error.  
 
Beyond modifying the reward function to 
improve the control of BSR accuracy precision, we must 
also train the RL agent to target a specific duration (12-15 
minutes) of a specific BSR range (70-90%), as specified 
by the high-dose treatment protocol. We can also consider 
developing and deploying multiple agents with different 
goals, trained by different reward functions through the 
PIBS treatment. We must also consider how we integrate 
the RL agent with real-world clinical settings. We 
currently envision keeping the clinician in the control 
loop, and also seek to limit the number of dosing 
adjustments (e.g. no more than 5 adjustments) over each 
treatment, so that the clinician is not overburdened.  
 
When we have demonstrated successful training 
in an RL agent, we plan to train the agents using patient-
models with different sex, height, age, and weight 
combinations. Performance of a trained RL agent will be 
tested on a patient testing set that has not been seen during 
training. We also plan to apply a noise model to the BSR 
signal itself. We can evaluate the intra-patient, and inter-
patient, and inter-treatment performance of a RL-based 
control approach for PIBS. If successful, these 
improvements in BSR control will directly support our 
clinical investigation of PIBS and other potential 
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